Short answer: the first wave has started, but the spree has not. What we are seeing in October 2026 is the opening act. A handful of small, adjacency driven deals have closed. Two category leaders have raised enough capital to buy things. The NHS has begun to buy in bulk, which changes who survives. Regulation has become a real fixed cost. The conditions for a busier twelve to eighteen months are in place, but a "spree" is a forecast, not a fact and we will try to keep the tw

OpenEvidence has established itself as the preeminent artificial intelligence platform in United States clinical practice, commonly referred to across the digital health ecosystem as the "ChatGPT for Doctors". Conceived by serial technologist Daniel Nadler and machine learning researcher Zachary Ziegler, the platform was developed to address an acute structural crisis in modern medicine: the velocity of peer-reviewed biomedical literature, which currently doubles every 73 day